| Schedule of Basic and Diluted Net Income (Loss) per Share |
Basic
and diluted net income (loss) per share was calculated as follows:
Schedule of Basic and Diluted Net Income (Loss) per Share
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Numerator: | |
| | | |
| | | |
| | | |
| | |
| Net (loss) income | |
$ | (2,172 | ) | |
$ | 2,982 | | |
$ | (4,625 | ) | |
$ | 1,080 | |
| Less: undistributed earnings attributable to participating warrant holders | |
| - | | |
| (225 | ) | |
| - | | |
$ | (80 | ) |
| Net income (loss) attributable to common shareholders – basic | |
$ | (2,172 | ) | |
$ | 2,757 | | |
$ | (4,625 | ) | |
$ | 1,000 | |
| Reallocation of undistributed earnings attributable to participating warrant holders | |
| - | | |
$ | 9 | | |
| - | | |
| 3 | |
| Net income (loss) attributable to common shareholders – diluted | |
$ | (2,172 | ) | |
$ | 2,766 | | |
$ | (4,625 | ) | |
$ | 1,003 | |
| Denominator: | |
| | | |
| | | |
| | | |
| | |
| Weighted average shares of common stock outstanding – basic | |
| 58,019,837 | | |
| 36,835,945 | | |
| 56,793,139 | | |
| 35,477,382 | |
| Net income (loss) per share attributable to common shares – basic | |
$ | (0.04 | ) | |
$ | 0.07 | | |
$ | (0.08 | ) | |
$ | 0.03 | |
| Effect of dilutive securities | |
| | | |
| | | |
| | | |
| | |
| Restricted stock units | |
| - | | |
| 1,106,197 | | |
| - | | |
| 1,160,296 | |
| Warrants | |
| - | | |
| 33,779 | | |
| - | | |
| 60,120 | |
| Loan extensions | |
| - | | |
| 430,000 | | |
| - | | |
| 430,000 | |
| Dilutive potential common shares | |
| - | | |
| 1,569,976 | | |
| - | | |
| 1,650,416 | |
| Weighted average shares of common stock outstanding – diluted | |
| 58,019,837 | | |
| 38,405,921 | | |
| 56,793,139 | | |
| 37,127,798 | |
| Net income (loss) per share attributable to common shares – diluted | |
$ | (0.04 | ) | |
$ | 0.07 | | |
$ | (0.08 | ) | |
$ | 0.03 | |
|
| Schedule of Antidilutive Earnings Per Share |
Schedule of Antidilutive Earnings Per Share
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Restricted stock units | |
| 4,577,611 | | |
| 743,907 | | |
| 4,577,611 | | |
| 689,808 | |
| Warrants for Common Stock | |
| 12,181,019 | | |
| 12,330,336 | | |
| 12,181,019 | | |
| 12,303,995 | |
| Total common stock equivalents | |
| 16,758,630 | | |
| 13,074,243 | | |
| 16,758,630 | | |
| 12,993,803 | |
|